ICAM-1 orchestrates the abscopal effect of tumor radiotherapy

• Published in: Proceedings of the National Academy of Sciences - PNAS Vol. 118; no. 14
• Main Authors: Zhao, Yang, Zhang, Ting, Wang, Yanpu, Lu, Dehua, Du, Jinhong, Feng, Xun, Zhou, Haoyi, Liu, Ning, Zhu, Hua, Qin, Shangbin, Liu, Chenxin, Gao, Xianshu, Yang, Zhi, Liu, Zhaofei
• Format: Journal Article
• Language: English
• Published: United States National Academy of Sciences 06.04.2021
• Subjects: Adenoviridae; Animals; Antineoplastic Agents - administration & dosage; Biological Sciences; Biomarkers - metabolism; CD8-Positive T-Lymphocytes - drug effects; CD8-Positive T-Lymphocytes - metabolism; Drug Evaluation, Preclinical; Imiquimod - administration & dosage; Intercellular Adhesion Molecule-1 - administration & dosage; Intercellular Adhesion Molecule-1 - metabolism; Lymphocytes, Tumor-Infiltrating - drug effects; Lymphocytes, Tumor-Infiltrating - metabolism; Mice; Mice, Inbred BALB C; Nanoparticles; Neoplasms, Experimental - diagnostic imaging; Neoplasms, Experimental - immunology; Neoplasms, Experimental - metabolism; Neoplasms, Experimental - radiotherapy; Positron-Emission Tomography; radiotherapy; ICAM-1; abscopal effect; positron emission tomography; Toll-like receptor
• ISSN: 0027-8424; 1091-6490
• DOI: 10.1073/pnas.2010333118

Compelling evidence indicates that radiotherapy (RT) has a systemic inhibitory effect on nonirradiated lesions (abscopal effect) in addition to the ablation of irradiated tumors. However, this effect occurs only in rare circumstances in clinical practice, and mechanisms underlying the abscopal effect of RT are neither fully understood nor therapeutically utilized. Here we identified that intercellular adhesion molecule-1 (ICAM-1), an inducible glycoprotein of the immunoglobulin superfamily, is up-regulated in nonirradiated tumors responsive to RT. ICAM-1 expression in preclinical animal models can be noninvasively detected by optical imaging and positron emission tomography (PET) using near-infrared fluorescence dye- and Cu-labeled imaging probes that we synthesized, respectively. Importantly, the expression levels of ICAM-1 determined by quantitative PET imaging showed a strong negative linear correlation with the growth of nonirradiated tumors. Moreover, genetic or pharmacologic up-regulation of ICAM-1 expression by either an intratumoral injection of engineered recombinant adenovirus or systemic administration of a Toll-like receptor 7 agonist-capsulated nanodrug could induce markedly increased abscopal responses to local RT in animal models. Mechanistic investigation revealed that ICAM-1 expression can enhance both the activation and tumor infiltration of CD8 T cells to improve the responses of the nonirradiated tumors to RT. Together, our findings suggest that noninvasive PET imaging of ICAM-1 expression could be a powerful means to predict the responses of nonirradiated tumors to RT, which could facilitate the exploration of new combination RT strategies for effective ablation of primary and disseminated lesions.